‹ All Posts
Tejaswi

5 mins ago · SEBI Registration INA200015176

Shaily Engineering Plastics: Healthcare Now 55% of Sales

SHAILY Shaily Engineering Plastics (NSE : SHAILY) manufactures precision-moulded plastic components for healthcare, consumer and industrial applications. Its healthcare business covers pen injectors, auto-injectors and respiratory inhalers, combining injection moulding with automated assembly and product validation. What happened: In Q2 FY27, revenue grew 24% year on year to Rs 319.5 crore. EBITDA rose 25% to Rs 101.8 crore, with margin at 31.9%. PAT grew 20% to Rs 61.3 crore. Healthcare revenue grew 78% to Rs 175.1 crore, accounting for 55% of consolidated revenue, up from 38% a year earlier. The company delivered 10.4 million devices in Q2 and signed two new contracts for IP-led platforms. Why it matters: Additional pen-injector capacity of 25 million units is being commissioned, with commercial sales targeted for December 2026. The company is also developing a reusable GLP-1 auto-injector with 80% of development done, still seeking a pharma partner. Consumer revenue fell 14% to Rs 115.9 crore on weak home-furnishing demand in Europe and the US. What I am watching: Whether the December 2026 capacity commissioning converts to revenue on schedule. The company also plans semiconductor packaging with trial production in Q3 FY27 and commercial shipments in Q4 FY27 with a Korean partner, though management expects this opportunity to take 36 months to develop. My stance: Shaily trades at approximately 71 times earnings, pricing in a sustained shift toward higher-margin healthcare device work. ROCE is 41.1% and ROE 29.7%. The valuation is demanding, but the shift from components to qualified drug-delivery platforms is clear and execution has been consistent. I do not hold a position in Shaily Engineering Plastics at the time of writing. This is not investment advice.

#EquityResearch#HiddenGems#FundamentalViews#WatchOutFor
463 likes·64 comments